Immunovant, a rising star in the clinical-stage biopharmaceutical world, is committed to developing cutting-edge monoclonal antibodies to better treat autoimmune diseases. Their primary focus is on batoclimab - a novel, fully human monoclonal antibody designed to selectively target and inhibit the neonatal fragment crystallizable receptor. Already in Phase IIa clinical trials, batoclimab has shown promising results in treating both myasthenia gravis and thyroid eye disease. Furthermore, Phase II clinical trials have been initiated for the treatment of warm autoimmune hemolytic anemia. Headquartered in the heart of New York City, Immunovant was founded in 2018 and is a forward-thinking subsidiary of Roivant Sciences Ltd. They clearly have their sights set on a grand future in the competitive biopharmaceutical field.